<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/ms2025-365</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-9424</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОСМЕТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COSMETOLOGY</subject></subj-group></article-categories><title-group><article-title>Комплексные протоколы коррекции возрастных изменений, вызванных лекарственно-индуцированной потерей подкожно-жировой клетчатки лица и тела, с помощью препаратов на основе PLA</article-title><trans-title-group xml:lang="en"><trans-title>Complex protocols for correction of age-related changes caused by drug-induced loss of subcutaneous fat tissue of the face and body using a PLA-based preparation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8657-9559</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моржанаева</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Morzhanaeva</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моржанаева Мария Андреевна - к.м.н., врач-косметолог, генетический консультант, ООО «Мелситек», клиника косметологии; ООО «Мелситек», генетическая лаборатория “Melsytech Genetics”.</p><p>127473, Москва, 2-й Щемиловский пер., д. 4; 603087, Нижний Новгород, ул. Верхне-Печерская, д. 7д</p></bio><bio xml:lang="en"><p>Maria A. Morzhanaeva - Cand. Sci. (Med.), Cosmetologist, Expert genetic, Melsytech LLC, Cosmetology Clinic; Melsytech LLC, Genetic Laboratory “Melsytech Genetics”.</p><p>4, 2nd Shchemilovsky Lane, Moscow, 127473; 7d, Verkhne-Pecherskaya St., Nizhny Novgorod, 603087</p></bio><email xlink:type="simple">maria_morzhanaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5885-4872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Свечникова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Svechnikova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Свечникова Елена Владимировна - д.м.н., заведующая отделением дерматовенерологии и косметологии, Поликлиника №1 Управления делами Президента РФ; профессор кафедры кожных и венерических болезней, Российский биотехнологический университет (РОСБИОТЕХ).</p><p>119002, Москва, пер. Сивцев Вражек, д. 26/28; 125080, Москва, Волоколамское шоссе, д. 11</p></bio><bio xml:lang="en"><p>Elena V. Svechnikova - Dr. Sci. (Med.), Head of the Department of Dermatovenereology and Cosmetology, Polyclinic No. 1 of the Administrative Department of the Russian Federation; Professor of the Department of Skin and Venereal Diseases; Russian BU.</p><p>26/28, Sivtsev Vrazhek Lane, Moscow, 119002; 11, Volokolamskoe Shosse, Moscow, 125080</p></bio><email xlink:type="simple">elene-elene@bk.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0314-7035</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горская</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorskaya</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горская Антонина Александровна - врач-косметолог, руководитель, клиника O’LIVE.</p><p>603022, Нижний Новгород, ул. Тимирязева, д. 31а</p></bio><bio xml:lang="en"><p>Antonina A. Gorskaya - Cosmetologist, Head/</p><p>31a, Timiryazev St., Nizhny Novgorod, 603022</p></bio><email xlink:type="simple">aa.gorskaya@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5619-6757</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артемьева</surname><given-names>Н. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Artemyeva</surname><given-names>N. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артемьева Наталья Олеговна - к.м.н., врач-диетолог, генетик, экспертная многопрофильная клиника «ОМНИУС».</p><p>119192, Москва, ул. Мосфильмовская, д. 53</p></bio><bio xml:lang="en"><p>Natalya O. Artemyeva - Cand. Sci. (Med.), Nutritionist, Geneticist, Expert Multidisciplinary Clinic “OMNIUS”.</p><p>53, Mosfilmovskaya St., Moscow, 119192</p></bio><email xlink:type="simple">natalya.artemeva.89@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ООО «Мелситек», клиника косметологии; ООО «Мелситек», генетическая лаборатория “Melsytech Genetics”</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Melsytech LLC, Cosmetology Clinic; Melsytech LLC, Genetic Laboratory “Melsytech Genetics”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Поликлиника №1 Управления делами Президента Российской Федерации; Российский биотехнологический университет (РОСБИОТЕХ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Polyclinic No. 1 of the Administrative Department of the Russian Federation; Russian Biotechnological University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Клиника O’LIVE</institution><country>Россия</country></aff><aff xml:lang="en"><institution>O’LIVE Clinic</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Экспертная многопрофильная клиника «ОМНИУС»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Expert Multidisciplinary Clinic “OMNIUS”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2025</year></pub-date><volume>0</volume><issue>14</issue><fpage>202</fpage><lpage>211</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Моржанаева М.А., Свечникова Е.В., Горская А.А., Артемьева Н.О., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Моржанаева М.А., Свечникова Е.В., Горская А.А., Артемьева Н.О.</copyright-holder><copyright-holder xml:lang="en">Morzhanaeva M.A., Svechnikova E.V., Gorskaya A.A., Artemyeva N.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/9424">https://www.med-sovet.pro/jour/article/view/9424</self-uri><abstract><p>С ростом популярности агонистов рецептора глюкагоноподобного пептида-1 (GLP-1RA) общественность и сообщество косметологов и пластических хирургов ввели новую терминологию для характеристики некоторых непреднамеренных эффектов этих препаратов. Такие термины, как «лицо Ozempic®» и «тело Ozempic®», получили широкое распространение для обозначения потери объема тканей в результате терапии семаглутидом. Был проведен поиск в Google Trends, чтобы уточнить общественное мнение об агонистах рецептора GLP-1 и их связь с морфологическими изменениями, наблюдаемыми при медикаментозном снижении веса. Существуют некоторые данные, предполагающие, что GLP-1RA может также ускорять старение кожи, воздействуя на клетки в слое жировой ткани и подавляя их пролиферацию и метаболическую активность. GLP-1RA влияет на дермальную белую жировую ткань (DWAT) и стволовые клетки, полученные из жировой ткани (ADSCs), и, возможно, на гормональную регуляцию и мышцы лица. Для коррекции изменений, связанных с риском возникновения резкого увеличения кожного лоскута и потери объема тканей, используется широкий арсенал аппаратных и инъекционных методов. Особое место занимают инъекционные коллагеностимуляторы на основе полимолочной кислоты (PLA). После введения филлеры PLA вызывают дифференциацию макрофагов в подтип M2, который, как известно, индуцирует выработку коллагена за счет увеличения экспрессии TGF-β в фибробластах и является биосовместимым материалом, который гидролизуется до воды и углекислого газа. После введения микросферы PDLLA остаются локализованными в тканях, способствуя привлечению миофибробластов и ADSCs, что актуально для пациентов с лекарственно-индуцированной потерей подкожно-жировой клетчатки. В данном обзоре представлены основные методы коррекции и варианты сочетанных протоколов, приведены клинические случаи.</p></abstract><trans-abstract xml:lang="en"><p>With the increasing popularity of glucagon-like peptide-1 receptor agonists (GLP-1RA), the public and the cosmetic and plastic surgery community have coined new terminology to characterize some of the unintended effects of these drugs. Terms such as “Ozempic® face” and “Ozempic® body” have come into common usage to describe the loss of tissue volume resulting from semaglutide therapy. A Google Trends search was conducted to clarify public perceptions of GLP-1 receptor agonists and their relationship to the morphologic changes observed with drug-induced weight loss. There is some evidence to suggest that GLP-1RA may also accelerate skin aging by targeting cells in the adipose tissue layer and suppressing their proliferation and metabolic activity. GLP-1RA affects dermal white adipose tissue (DWAT) and adipose-derived stem cells (ADSCs), and possibly hormonal regulation and facial muscles. A wide range of hardware and injection methods are used to correct changes associated with the risk of a sharp increase in the skin flap and loss of tissue volume. A special place is occupied by injectable collagen stimulators based on polylactic acid (PLA). After administration, PLA fillers cause differentiation of macrophages into the M2 subtype, which is known to induce collagen production by increasing the expression of TGF-β in fibroblasts and is a biocompatible material that is hydrolyzed to water and carbon dioxide. After administration, PDLLA microspheres remain localized in the tissues, promoting the attraction of myofibroblasts and ADSCs, which is important in patients with drug-induced loss of subcutaneous fat. This review presents the main correction methods and options for combined protocols, and provides clinical cases.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>полимолочная кислота</kwd><kwd>векторный лифтинг</kwd><kwd>PLA</kwd><kwd>коллагеностимуляторы</kwd><kwd>Ozempic® face</kwd><kwd>Ozempic® body</kwd><kwd>агонисты рецепторов глюкагоноподобного пептида-1</kwd><kwd>ADSCs</kwd><kwd>семаглутид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>polylactic acid</kwd><kwd>vector lifting</kwd><kwd>PLA</kwd><kwd>collagen stimulators</kwd><kwd>Ozempic® face</kwd><kwd>Ozempic® body</kwd><kwd>glucagon-like peptide-1 receptor agonists</kwd><kwd>ADSCs</kwd><kwd>semaglutide</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mansour MR, Hannawa OM, Yaldo MM, Nageeb EM, Chaiyasate K. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225–227. https://doi.org/10.1016/j.bjps.2024.07.051.</mixed-citation><mixed-citation xml:lang="en">Mansour MR, Hannawa OM, Yaldo MM, Nageeb EM, Chaiyasate K. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. J Plast Reconstr Aesthet Surg. 2024;96:225–227. https://doi.org/10.1016/j.bjps.2024.07.051.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. J Plast Reconstr Aesthet Surg. 2023;81:97–98. https://doi.org/10.1016/j.bjps.2023.04.057.</mixed-citation><mixed-citation xml:lang="en">Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. J Plast Reconstr Aesthet Surg. 2023;81:97–98. https://doi.org/10.1016/j.bjps.2023.04.057.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or “Ozempic Face”: Demystifying A Social Media Phenomenon. J Drugs Dermatol. 2024;23(1):1367–1368. https://doi.org/10.36849/JDD.7613.</mixed-citation><mixed-citation xml:lang="en">Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural Weight Loss or “Ozempic Face”: Demystifying A Social Media Phenomenon. J Drugs Dermatol. 2024;23(1):1367–1368. https://doi.org/10.36849/JDD.7613.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ridha Z, Fabi SG, Zubar R, Dayan SH. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthet Surg J. 2024;44(11):NP809–NP818. https://doi.org/10.1093/asj/sjae132.</mixed-citation><mixed-citation xml:lang="en">Ridha Z, Fabi SG, Zubar R, Dayan SH. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthet Surg J. 2024;44(11):NP809–NP818. https://doi.org/10.1093/asj/sjae132.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390(3):613–618. https://doi.org/10.1016/j.bbrc.2009.10.015.</mixed-citation><mixed-citation xml:lang="en">Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun. 2009;390(3):613–618. https://doi.org/10.1016/j.bbrc.2009.10.015.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kim WS, Park BS, Kim HK, Park JS, Kim KJ, Choi JS et al. Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress. J Dermatol Sci. 2008;49(2):133–142. https://doi.org/10.1016/j.jdermsci.2007.08.004.</mixed-citation><mixed-citation xml:lang="en">Kim WS, Park BS, Kim HK, Park JS, Kim KJ, Choi JS et al. Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress. J Dermatol Sci. 2008;49(2):133–142. https://doi.org/10.1016/j.jdermsci.2007.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol. 2015;402:43–50. https://doi.org/10.1016/j.mce.2014.12.021.</mixed-citation><mixed-citation xml:lang="en">Cantini G, Di Franco A, Samavat J, Forti G, Mannucci E, Luconi M. Effect of liraglutide on proliferation and differentiation of human adipose stem cells. Mol Cell Endocrinol. 2015;402:43–50. https://doi.org/10.1016/j.mce.2014.12.021.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zouboulis CC, Gould K. Premature skin ageing signs due to androgen deprivation therapy. J Eur Acad Dermatol Venereol. 2024;38(2):e197–e198. https://doi.org/10.1111/jdv.19554.</mixed-citation><mixed-citation xml:lang="en">Zouboulis CC, Gould K. Premature skin ageing signs due to androgen deprivation therapy. J Eur Acad Dermatol Venereol. 2024;38(2):e197–e198. https://doi.org/10.1111/jdv.19554.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Li P, Tang Z, Dou Q, Feng B. Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE-/mice. Ann Transl Med. 2019;7(16):369. https://doi.org/10.21037/atm.2019.06.74.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Li P, Tang Z, Dou Q, Feng B. Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE-/mice. Ann Transl Med. 2019;7(16):369. https://doi.org/10.21037/atm.2019.06.74.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metab. 2018;28(3):337–352. https://doi.org/10.1016/j.cmet.2018.08.014.</mixed-citation><mixed-citation xml:lang="en">Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metab. 2018;28(3):337–352. https://doi.org/10.1016/j.cmet.2018.08.014.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Doyle AG, Herbein G, Montaner LJ, Minty AJ, Caput D, Ferrara P, Gordon S. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol. 1994;24(6):1441–1445. https://doi.org/10.1002/eji.1830240630.</mixed-citation><mixed-citation xml:lang="en">Doyle AG, Herbein G, Montaner LJ, Minty AJ, Caput D, Ferrara P, Gordon S. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol. 1994;24(6):1441–1445. https://doi.org/10.1002/eji.1830240630.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wu YH, Cheng ML, Ho HY, Chiu DT, Wang TC. Telomerase prevents accelerated senescence in glucose-6-phosphate dehydrogenase (G6PD)-deficient human fibroblasts. J Biomed Sci. 2009;16(1):18. https://doi.org/10.1186/1423-0127-16-18.</mixed-citation><mixed-citation xml:lang="en">Wu YH, Cheng ML, Ho HY, Chiu DT, Wang TC. Telomerase prevents accelerated senescence in glucose-6-phosphate dehydrogenase (G6PD)-deficient human fibroblasts. J Biomed Sci. 2009;16(1):18. https://doi.org/10.1186/1423-0127-16-18.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HJ, Kim B, Byun HJ, Yu L, Nguyen TM, Nguyen TH et al. Resolvin D1 Suppresses H2O2-Induced Senescence in Fibroblasts by Inducing Autophagy through the miR-1299/ARG2/ARL1 Axis. Antioxidants. 2021;10(12):1924. https://doi.org/10.3390/antiox10121924.</mixed-citation><mixed-citation xml:lang="en">Kim HJ, Kim B, Byun HJ, Yu L, Nguyen TM, Nguyen TH et al. Resolvin D1 Suppresses H2O2-Induced Senescence in Fibroblasts by Inducing Autophagy through the miR-1299/ARG2/ARL1 Axis. Antioxidants. 2021;10(12):1924. https://doi.org/10.3390/antiox10121924.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Saw CL, Yang AY, Huang MT, Liu Y, Lee JH, Khor TO et al. Nrf2 null enhances UVB-induced skin inflammation and extracellular matrix damages. Cell Biosci. 2014;4:39. https://doi.org/10.1186/2045-3701-4-39.</mixed-citation><mixed-citation xml:lang="en">Saw CL, Yang AY, Huang MT, Liu Y, Lee JH, Khor TO et al. Nrf2 null enhances UVB-induced skin inflammation and extracellular matrix damages. Cell Biosci. 2014;4:39. https://doi.org/10.1186/2045-3701-4-39.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Oh S, Rho NK, Byun KA, Yang JY, Sun HJ, Jang M et al. Combined Treatment of Monopolar and Bipolar Radiofrequency Increases Skin Elasticity by Decreasing the Accumulation of Advanced Glycated End Products in Aged Animal Skin. Int J Mol Sci. 2022;23(6):2993. https://doi.org/10.3390/ijms23062993.</mixed-citation><mixed-citation xml:lang="en">Oh S, Rho NK, Byun KA, Yang JY, Sun HJ, Jang M et al. Combined Treatment of Monopolar and Bipolar Radiofrequency Increases Skin Elasticity by Decreasing the Accumulation of Advanced Glycated End Products in Aged Animal Skin. Int J Mol Sci. 2022;23(6):2993. https://doi.org/10.3390/ijms23062993.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Duan W, Zhang R, Guo Y, Jiang Y, Huang Y, Jiang H, Li C. Nrf2 activity is lost in the spinal cord and its astrocytes of aged mice. In Vitro Cell Dev Biol Anim. 2009;45(7):388–397. https://doi.org/10.1007/s11626-009-9194-5.</mixed-citation><mixed-citation xml:lang="en">Duan W, Zhang R, Guo Y, Jiang Y, Huang Y, Jiang H, Li C. Nrf2 activity is lost in the spinal cord and its astrocytes of aged mice. In Vitro Cell Dev Biol Anim. 2009;45(7):388–397. https://doi.org/10.1007/s11626-009-9194-5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Magacho-Vieira FN, Vieira AO, Soares A Jr, Alvarenga HCL, de Oliveira Junior IRA, Daher JAC et al. Consensus Recommendations for the Reconstitution and Aesthetic Use of Poly-D,L-Lactic Acid Microspheres. Clin Cosmet Investig Dermatol. 2024;17:2755–2765. https://doi.org/10.2147/CCID.S497691.</mixed-citation><mixed-citation xml:lang="en">Magacho-Vieira FN, Vieira AO, Soares A Jr, Alvarenga HCL, de Oliveira Junior IRA, Daher JAC et al. Consensus Recommendations for the Reconstitution and Aesthetic Use of Poly-D,L-Lactic Acid Microspheres. Clin Cosmet Investig Dermatol. 2024;17:2755–2765. https://doi.org/10.2147/CCID.S497691.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lee KWA, Chan LKW, Lee AWK, Lee CH, Wong STH, Yi KH. Poly-D,L-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers. 2024;16(18):2583. https://doi.org/10.3390/polym16182583.</mixed-citation><mixed-citation xml:lang="en">Lee KWA, Chan LKW, Lee AWK, Lee CH, Wong STH, Yi KH. Poly-D,L-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers. 2024;16(18):2583. https://doi.org/10.3390/polym16182583.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lin CY, Lin JY, Yang DY, Lee SH, Kim JY, Kang M. Efficacy and safety of polyD,L-lactic acid microspheres as subdermal fillers in animals. Plast Aesthet Res. 2019;6:16. https://doi.org/10.20517/2347-9264.2019.23.</mixed-citation><mixed-citation xml:lang="en">Lin CY, Lin JY, Yang DY, Lee SH, Kim JY, Kang M. Efficacy and safety of polyD,L-lactic acid microspheres as subdermal fillers in animals. Plast Aesthet Res. 2019;6:16. https://doi.org/10.20517/2347-9264.2019.23.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Oh S, Seo SB, Kim G, Batsukh S, Park CH, Son KH, Byun K. Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin. Antioxidants. 2023;12(6):1204. https://doi.org/10.3390/antiox12061204.</mixed-citation><mixed-citation xml:lang="en">Oh S, Seo SB, Kim G, Batsukh S, Park CH, Son KH, Byun K. Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin. Antioxidants. 2023;12(6):1204. https://doi.org/10.3390/antiox12061204.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
